Key facts
- Pandorum’s last known valuation is $46.5M (Mar 2024).
- It has raised $43.7M; the latest was Later Stage VC ($18.0M) in Feb 2026.
- Notable investors include US National Science Foundation, Endless Frontier Labs, Indian Angel Network, Ashish Kacholia, Binny Bansal — 40 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 40 names
- ·Watchlist + deal alerts for Pandorum
- ·The full record, as it builds
Funding rounds
No funding rounds for Pandorum are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pandorum
Developer of functional human tissues designed for tissue engineering and regenerative medicine. The company's experimental-stage human liver tissue is created using three-dimensional printing technology and acts as an artificial liver during liver failures or liver transplantation, and takes less time to regenerate for medical research and therapeutic applications, enabling surgeons to perform painless liver surgeries to advance regenerative therapies.
- Sector
- Healthcare
- HQ
- Bengaluru, India
- Founded
- 2009
- Employees
- 40
- Website
- pandorum.com/
- Ownership
- Privately Held (backing)
Pandorum doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pandorum shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pandorum in its N-PORT filings yet. We sweep new filings monthly.